RIPK1 and atherosclerosis: Taken together, these data suggest that RIPK1 inhibition might lead to the foam cell accumulation in the plaque both by promoting foam cell formation (via upregulating lipid uptake) and by suppressing their cell death, thus exacerbating late-stage atherosclerosis.